# US 2015/0031658 A1 · Ethoxyphenyl thienyl compounds and methods for the treatment of bacterial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031658 A1
- Document ID: US20150031658A1
- Status: Published application
- Kind: A1
- Application number: 14/514,725
- Filed: 2014-10-15
- Published: 2015-01-29
- Earliest claimed: 2013-06-14
- Assignees: Duke University; University of Kansas; Southern Research Institute
- Applicants: Duke University; The University of Kansas; Southern Research Institute
- Inventors: Patrick C. Seed; Carlos C. Goller; Apurba Dutta; Brooks Maki; Frank Schoenen; James Noah; Lucile White
- Web page: https://patentgrep.com/patent/US20150031658A1

## CPC

- C07D 333/24: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61K 31/381: having five-membered rings
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.

## Claims

### Claim 1

A method of inhibiting capsule biogenesis in a bacterium which comprises administering to the bacterium an effective amount of a composition comprising
each R1, R2, and R3 may independently be aryl, C1-8 alkyl, C1-8 alkyl(aryl), C1-8 alkoxy, C1-8 alkoxy aryl, C1-8 haloalkoxy, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, —CF3, —(CH2)xNR4R5, —CN, —CONR4R5, —COR4, —CO2(CH2)xNR4R5, —CO2R4, haloaryl, halogen, heteroaryl, hydroxyl, —N3, —NHCOR4, —NHSO2C1-8 alkyl, —NHCO2C1-8 alkyl, —NO2, —NR4R5, —O(CH2)xNR4R5, —O(CH2)xCO2R4, —OCOC1-8 alkyl, —OCO(CH2)xNR4R5, —SO(1-3)R4, or —SR4; each R4 and R4 are independently aryl, C1-8 alkyl, C1-8 alkyl alcohol, C1-8 alkyl amino, C1-8 alkyl amido, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl), C1-8 alkyl guanidinyl, C1-8 alkyl heteroaryl, C1-8 alkyl imidazolyl, C1-8 alkyl indolyl, C1-8 alkyl thioether, C1-8 alkyl thiol, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, or H; or R4 and R5 together make a 4-8 member ring which may be substituted with one or more heteroatoms; n is 0, 1, 2, 3, 4 or 5; and each x is independently 0-8

### Claim 2 (depends on 1)

The method of claim 1, wherein the capsule biogenesis is K1 or K5 capsule biogenesis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the bacterium is a gram-negative bacteria.

### Claim 4 (depends on 3)

The method of claim 3, wherein the gram-negative bacteria is Campylobacter jejuni, Enterobacter cloacae, Haemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Methicillin-resistant Staphylococcus aureus (MRSA), Neisseria meningitides, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella typhimurium, Serratia marcescens, Staphylococcus aureus or a combination thereof.

### Claim 5

A method of treating a subject suffering from a bacterial infection comprising administering a therapeutically effective amount of a composition comprising
each R1, R2, and R3 may independently be aryl, C1-8 alkyl, C1-8 alkyl(aryl), C1-8 alkoxy, C1-8 alkoxy aryl, C1-8 haloalkoxy, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, —CF3, —(CH2)xNR4R5, —CN, —CONR4R5, —COR4, —CO2(CH2)xNR4R5, —CO2R4, haloaryl, halogen, heteroaryl, hydroxyl, —N3, —NHCOR4, —NHSO2C1-8 alkyl, —NHCO2C1-8 alkyl, —NO2, —NR4R5, —O(CH2)xNR4R5, —O(CH2)xCO2R4, —OCOC1-8 alkyl, —OCO(CH2)xNR4R5, —SO(1-3)R4, or —SR4; each R4 and R4 are independently aryl, C1-8 alkyl, C1-8 alkyl alcohol, C1-8 alkyl amino, C1-8 alkyl amido, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl), C1-8 alkyl guanidinyl, C1-8 alkyl heteroaryl, C1-8 alkyl imidazolyl, C1-8 alkyl indolyl, C1-8 alkyl thioether, C1-8 alkyl thiol, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, or H; or R4 and R5 together make a 4-8 member ring which may be substituted with one or more heteroatoms; n is 0, 1, 2, 3, 4 or 5; and each x is independently 0-8, and/or salts thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the bacterium is a gram-negative bacteria.

### Claim 7 (depends on 6)

The method of claim 6, wherein the gram-negative bacteria is Campylobacter jejuni, Enterobacter cloacae, Haemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Methicillin-resistant Staphylococcus aureus (MRSA), Neisseria meningitides, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella typhimurium, Serratia marcescens, Staphylococcus aureus or a combination thereof.

### Claim 8 (depends on 5)

The method of claim 5, further comprising administering an agent that targets a bacterial cell wall.

### Claim 9 (depends on 8)

The method of claim 8, wherein the agent is a penicillin or a cephalosporin.

### Claim 10 (depends on 5)

The method of claim 5, wherein the bacterial infection is a urinary tract infection (UTI), a bladder infection, a kidney infection, or a disseminated staphylococcus infection.

### Claim 11 (depends on 10)

The method of claim 10, wherein the bacterial infection is a urinary tract infection (UTI).

### Claim 12 (depends on 10)

The method of claim 10, wherein the bacterial infection is a bladder infection.

### Claim 13 (depends on 10)

The method of claim 10, wherein the bacterial infection is a kidney infection.

### Claim 14 (depends on 5)

The method of claim 5, wherein the subject is a mammal.

### Claim 15 (depends on 14)

The method of claim 14, wherein the mammal is a human.

### Claim 16

A screening method for identifying compounds capable of inhibiting capsule biogenesis in a bacterium, the method comprising, consisting of, or consisting essentially of (a) growing in a culture a bacterium in the presence of at least one compound of interest; (b) adding the bacteriophage K1F to the culture; and (c) selecting the culture where bacterial growth is present.

### Claim 17

A compound having the structure below:
each R1, R2, and R3 may independently be aryl, C1-8 alkyl, C1-8 alkyl(aryl), C1-8 alkoxy, C1-8 alkoxy aryl, C1-8 haloalkoxy, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, —CF3, —(CH2)xNR4R5, —CN, —CONR4R5, —COR4, —CO2(CH2)xNR4R5, —CO2R4, haloaryl, halogen, heteroaryl, hydroxyl, —N3, —NHCOR4, —NHSO2C1-8 alkyl, —NHCO2C1-8 alkyl, —NO2, —NR4R5, —O(CH2)xNR4R5, —O(CH2)xCO2R4, —OCOC1-8 alkyl, —OCO(CH2)xNR4R5, —SO(1-3)R4, or —SR4; each R4 and R4 are independently aryl, C1-8 alkyl, C1-8 alkyl alcohol, C1-8 alkyl amino, C1-8 alkyl amido, C1-8 alkyl(aryl), C1-8 alkyl (C3-8 cycloalkyl), C1-8 alkyl guanidinyl, C1-8 alkyl heteroaryl, C1-8 alkyl imidazolyl, C1-8 alkyl indolyl, C1-8 alkyl thioether, C1-8 alkyl thiol, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, or H; or R4 and R5 together make a 4-8 member ring which may be substituted with one or more heteroatoms; n is 0, 1, 2, 3, 4 or 5; and each x is independently 0-8, and/or salts thereof.

### Claim 18 (depends on 17)

The compound of claim 17, having the structure
wherein each R1, R6, R7 and R8 may independently be C1-8 alkyl, C1-8 alkyl(aryl), C1-8 alkoxy, C1-8 haloalkoxy, C1-8 alkoxy aryl, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, —CF3, —CN, halogen, or hydrogen, and/or salts thereof.

### Claim 19 (depends on 17)

The compound of claim 17 having the structure
where R1 is C1-8 alkyl or C1-8 haloalkoxy and/or salts thereof.

### Claim 20 (depends on 17)

The compound of claim 17 having the structure
where each of R1 and R9 is C1-8 alkyl, C1-8 haloalkoxy or halogen, and/or salts thereof.
